Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
3.540
-0.210 (-5.60%)
At close: Feb 21, 2025, 4:00 PM
3.620
+0.080 (2.26%)
After-hours: Feb 21, 2025, 7:06 PM EST
Humacyte Employees
As of December 31, 2023, Humacyte had 185 total employees, including 183 full-time and 2 part-time employees. The number of employees increased by 21 or 12.80% compared to the previous year.
Employees
185
Change (1Y)
21
Growth (1Y)
12.80%
Revenue / Employee
n/a
Profits / Employee
-$826,308
Market Cap
455.49M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 185 | 21 | 12.80% |
Dec 31, 2022 | 164 | 18 | 12.33% |
Dec 31, 2021 | 146 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
HUMA News
- 2 days ago - Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA - Accesswire
- 4 weeks ago - Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting - GlobeNewsWire
- 5 weeks ago - HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
- 6 weeks ago - Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA - PRNewsWire
- 7 weeks ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - PRNewsWire
- 2 months ago - Humacyte Inc. Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Contact The Schall Law Firm - Accesswire
- 2 months ago - Humacyte stock may fail to sustain today's gains: find out more - Invezz
- 2 months ago - Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles - Hagens Berman - Accesswire